All In Biotech

Drug Trial Radar · NCT06969352

A Multicentre, Retrospective-prospective Real-world Study: to Evaluate the Effectiveness and Safety of Vorasidenib in Patients With Isocitrate Dehydrogenase IDH1/2 Mutant Grade 2 Astrocytoma or Oligodendroglioma (VICTORIA Study)

Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

62

Actual

Start

Sep 2, 2025

Primary completion

Apr 2028

Study completion Apr 2028

Sponsor

Sponsor type
Industry
Collaborators
Institut de Recherches Internationales Servier (I.R.I.S.); Hainan Boyan Medical Research Co. Ltd.; Fantastic Bioimaging Co., Ltd.; Clinical TrialService (Guangzhou) Co.,Ltd
First posted
May 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this Study is to evaluate the effectiveness and safety of Vorasidenib in Patients with Isocitrate dehydrogenase IDH1/2 mutant Grade 2 astrocytoma or oligodendroglioma, primary purposeis to evaluate the efficectiveness of Vorasidenib in glioma patients treated in routine clinical practice in In China, patients aged 12 and above with grade II or higher astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations. The main question it aims to answer is: if this trend is consistent with the efficacy observed in the INDIGO study, and there is not any new safety signal compared to previous research data? Researchers will compare to no treatment. Participants is not mandatory for a formal visit as it is a real-word study.However, due to the fact that patients will be treated with new drugs and need to collect data on major efficacy, regular visits should be performed in routine clinical practice. This study is a multicenter, retrospective-and prospective real-world study, There are treatment group (Vorasidenib) and external control group (untreated after surgery).

Conditions

  • Gliomas

Interventions

  • VorasidenibDrug

    Treatment group: recommended dosage in adults and paediatric patients 12 years of age and older: * For patients weighing at least 40 kg: 40 mg, orally, once daily. * For patients weighing less than 40 kg: 20 mg, orally, once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary efficacy endpointTime frame: at 6 months after the index date

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Tiantan Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • West China Lecheng Hospital Sichuan University

    Qionghai, Hainan, China

  • West China Hospital Sichuan University

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.